Inactive Instrument

Abpro Corporation

Equities

US0008501076

Abpro Appoints MacBeath as Chief Scientific Officer

March 21, 2017 at 12:08 pm

Abpro announced the expansion of its senior leadership team with the hiring of Dr. Gavin MacBeath, Ph.D. as Chief Scientific Officer. Dr. MacBeath brings over 16 years of experience in academia and the biotechnology industry, with expertise in systems biology, drug discovery, translational research, companion diagnostics, and clinical development of early-stage programs. He will report directly to Ian Chan, Chairman and Chief Executive Officer of Abpro.

Latest news about Abpro Corporation

Abpro Corporation entered into a term sheet to acquire Atlantic Coastal Acquisition Corp. II from a group of shareholders for approximately $770 million in a reverse merger transaction.	20/09/23	CI
Abpro Finalizes Strategic Partnership with Celltrion for Worldwide Development and Commercialization of Cancer Treatment Bispecific Antibody	21/09/22	CI
Abpro Corporation announced that it expects to receive $79.999992 million in funding	29/03/22	CI
Abpro Corporation Reports Its ABP 310 COVID Antibody Retains Neutralization Activity Against the SARS-CoV-2 Omicron Variant	09/12/21	CI
Abpro Announces Positive Phase 1 Results Demonstrating a Favorable Safety and Pharmacokinetic Profile of ABP 300, a Neutralizing Antibody Therapeutic for the Treatment of COVID-19	02/02/21	CI
Abpro Announces Initiation of Phase 2/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19	16/12/20	CI
Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for Treatment of COVID-19	20/10/20	CI
Abpro Forms Strategic Partnership to Advance Two Bispecific Antibody Candidates in Asian Markets	03/03/20	CI
Abpro Corporation announced that it expects to receive $29.999984 million in funding from Abpro Bio International, Inc.	30/10/19	CI
Abpro and NJCTTQ Enters Into Partnership for Development of Multiple Novel Bispecific Antibodies	28/02/19	CI
Abpro Corporation has withdrawn its IPO in the amount of $64 million.	16/05/18	CI
Abpro Corporation has filed an IPO in the amount of $69 million.	11/04/18	CI
Abpro Seeks Acquisitions	11/04/18	CI
Abpro Corporation announced that it has received $9.99999 million in funding	06/04/17	CI
Abpro Corporation announced a financing transaction	30/03/17	CI
Abpro Appoints MacBeath as Chief Scientific Officer	21/03/17	CI
Abpro Announces Agreements with Massachusetts General Hospital and Brigham and Women's Hospital to Co-Develop Therapeutics for Inflammation, Autoimmunity, Fibrosis, Oncology	19/05/16	CI
Abpro Announces Investment and Partnership with Essex Bio for Development of Antibody Therapeutics	06/04/16	CI
Abpro Corporation announced that it has received $3.5 million in funding from Essex Bio-Technology Limited	05/04/16	CI
Abpro Corporation announced that it has received $12.39 million in funding	23/03/16	CI
Abpro Corporation announced that it expects to receive $20 million in funding	10/03/16	CI
Abpro Corporation announced that it expects to receive $3.5 million in funding from Essex Bio-Technology Limited	21/01/16	CI

Chart Abpro Corporation

Duration

Period

More charts

Company Profile

Abpro Corporation, incorporated on August 18, 2004, is a biotechnology company that is engaged in developing antibody therapeutics. The Company is focused on antibody constructs for immuno-oncology, ophthalmology, and autoimmunity. With the Company's Divers Immune and MultiMab antibody discovery and engineering platforms, it is engaged in developing a pipeline of antibodies, both independently and through collaborations with global pharmaceutical and research institutions. The Company? s DiversImmune and MultiMab platforms and licensing strategy has generated a wide range pipeline of antibody product candidates, that includes ABP-100, ABP-110, ABP-130, ABP-300, ABP-500, ABP-201, ABP-200, and ABP-400. The Company's lead candidate, ABP-100, is a immuno-oncology TetraBi antibody that targets human epidermal growth factor receptor 2 (HER2) and cluster of differentiation 3 (CD3) for the treatment of HER2+ solid tumors, including breast, gastric, and endometrial cancers.

Sector

More about the company